FRX Forest Road Acquisition Corp

Forest Laboratories, Inc. Announces Launch of Clinical Trial Registry - http://www.forestclinicaltrials.com NEW YORK, Feb. 8 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE:FRX), an international pharmaceutical manufacturer and marketer, today announced that it has posted its first set of data on the Forest Clinical Trial Registry. Access to the registry is unrestricted and available at http://www.forestclinicaltrials.com/ or through a link from the Company's homepage http://www.frx.com/. The initial data posted includes results from all pediatric and adolescent studies for Forest's antidepressants Lexapro(R) and Celexa(R), as well as information regarding ongoing clinical studies for Forest products under development. Ivan Gergel, M.D., Chief Medical Officer at Forest, commented: "We fully support the posting of clinical study results to enable unrestricted access to data by physicians, patients, caregivers and other parties which may be beneficial in assessing available treatment options. Forest maintains high ethical standards and will continue to support measures which expand access to information regarding ongoing clinical studies as well as study results." (Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO ) Additional clinical trial information will be added to the registry as completed studies are summarized in registry format, as new studies are initiated, and as ongoing studies are completed and summarized. Full data summaries for completed qualifying clinical studies(1) will be summarized and posted to the registry by December 31, 2005. About Forest Laboratories and Its Products Forest Laboratories' growing line of products includes: Lexapro(R) (escitalopram oxalate), an SSRI antidepressant indicated for the initial and maintenance treatment of major depressive disorder and for generalized anxiety disorder in adults; Namenda(R) (memantine HCl), an N-methyl-D-aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Celexa(R) (citalopram HBr), an antidepressant for adults; Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker indicated for the treatment of hypertension; Benicar HCT(TM) (olmesartan medoxomil hydrochlorothiazide), an angiotensin receptor blocker and diuretic combination product indicated for the second-line treatment of hypertension; Campral(R)* (acamprosate calcium), a glutamate receptor modulator, indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation in combination with psychosocial support; Combunox(TM) (Oxycodone HCl and Ibuprofen) an opioid and NSAID combination indicated for the short-term management of acute, moderate to severe pain expected to be available in the U.S. early 2005. Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties that affect our business, including risk factors listed from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2004, and on form 10-Q for the periods ended June 30, 2004, and September 30, 2004. Actual results may differ materially from those projected. * Benicar(R) is a registered trademark of Sankyo Pharma, Inc., Campral(R) is a registered trademark under license from Merck Sante s.a.s., subsidiary of Merck KGaA, Darmstadt, Germany. (1) Summaries of completed studies are scheduled to be posted according to the following criteria: Phase IV: Within 1 year of study completion Phase III: Upon FDA approval and commercial availability Phase I/II: Upon FDA approval and commercial availability if results are material to the clinical use of the drug or care of the patients. The online availability of a summary may be delayed if Forest is required to perform certain actions to seek intellectual property protection. Summaries may also be delayed from online dissemination due to embargoes mandated by peer-reviewed journals while the study manuscript is under consideration for publication. http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGODATASOURCE: Forest Laboratories, Inc. CONTACT: CHARLES E. TRIANO, Vice President - Investor Relations of Forest Laboratories, Inc., +1-212-224-6714, Web site: http://www.frx.com/ http://www.forestclinicaltrials.com/

Copyright